Wondercel Biotech (shenzhen)

This early-phase study tests a new type of CAR-T cell therapy (UWD-00B) for people with multiple myeloma that has come back or not responded to other treatments. The therapy uses donor cells designed to attack a protein called BCMA on cancer cells. The main goals are to check saf…

This early-phase study tests a "universal" CAR-T cell therapy (UWD-CD19) for people with B-cell lymphoma or leukemia that has not responded to standard treatments. About 30 participants will receive a single infusion of these engineered immune cells after a short chemotherapy cou…

This early-phase study tests a new treatment called WD-01, which uses a patient's own immune cells modified to target a protein (GCC) found on colorectal cancer cells. The goal is to see if it is safe and can shrink tumors in people with metastatic colorectal cancer who have not …

This early-phase study tests a new type of CAR-T cell therapy (REVO-UWD-01) for people with metastatic colorectal cancer that has spread. The treatment uses specially engineered immune cells to target a protein called GCC found on cancer cells. The main goals are to find a safe d…

This early-phase study tests a new type of immune cell therapy called universal CAR-T cells for people with advanced liver or lung cancer who have not responded to standard treatments. The therapy targets a protein called GPC3 found on these cancer cells. The main goals are to fi…